Allogene Therapeutics Inc (ALLO)

06:01 AM

Allogene Therapeutics (ALLO) Upgraded to Outperform with Signifi - GuruFocus

06:01 AM

03:50 AM

Allogene Therapeutics (ALLO) Upgraded by Citizens to Market Outp - GuruFocus

03:50 AM

02:59 AM

Allogene upgraded at Citizens on discounted EPS, revenue multiple - Seeking Alpha

02:59 AM

11:25 AM

CG Oncology, Rich Sparkle Holdings, Liquidia And Other Big Stocks Moving Higher On Friday - Benzinga

11:25 AM

09:40 AM

Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? - Yahoo Finance

09:40 AM

03:42 AM

Citizens upgrades Allogene stock rating to Market Outperform on cancer therapy potential - Investing.com

03:42 AM

01:12 AM

Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T - Sahm

01:12 AM

Jan 08, 2026

Why Allogene Therapeutics Inc. stock is favored by pension fundsWeekly Profit Report & Free AI Powered Buy and Sell Recommendations - ulpravda.ru

Jan 08, 2026

Jan 08, 2026

Is Allogene Therapeutics Inc. stock a buy before product launchesRate Hike & Smart Money Movement Tracker - ulpravda.ru

Jan 08, 2026

Jan 08, 2026

Published on: 2026-01-08 23:56:20 - ulpravda.ru

Jan 08, 2026

Jan 08, 2026

Will Allogene Therapeutics Inc. stock reach Wall Street targetsJuly 2025 Decliners & Fast Gain Stock Trading Tips - ulpravda.ru

Jan 08, 2026

Jan 08, 2026

Can Allogene Therapeutics Inc. stock outperform in 2025 bull market2025 Major Catalysts & Risk Managed Trade Strategies - ulpravda.ru

Jan 08, 2026

Jan 08, 2026

How Allogene Therapeutics Inc. stock reacts to bond yieldsEarnings Growth Report & Consistent Profit Trade Alerts - ulpravda.ru

Jan 08, 2026

Jan 08, 2026

Allogene outlines 2026 clinical milestones for off-the-shelf CAR T - Investing.com India

Jan 08, 2026

Jan 08, 2026

Allogene Therapeutics interim futility analysis of MRD clearance from phase 2 Alpha3 trial planned for early Q2 2026 - MarketScreener

Jan 08, 2026

Jan 08, 2026

Off‑the‑shelf cell therapy for cancer and autoimmune disease faces 2026 test - Stock Titan

Jan 08, 2026

Jan 08, 2026

Is Allogene Therapeutics Inc. stock a buy in volatile marketsQuarterly Earnings Review & Access Risk Ratings for Every Stock - ulpravda.ru

Jan 08, 2026

Jan 07, 2026

UBS Initiates Coverage of Allogene Therapeutics (ALLO) with Buy Recommendation - Nasdaq

Jan 07, 2026

Jan 07, 2026

UBS Initiates Coverage on Allogene Therapeutics (ALLO) with 'Buy' Rating | ALLO Stock News - GuruFocus

Jan 07, 2026

Jan 07, 2026

UBS initiates coverage on Allogene stock with Buy rating, $8 price target By Investing.com - Investing.com South Africa

Jan 07, 2026

Jan 07, 2026

UBS initiates coverage on Allogene stock with Buy rating, $8 price target - Investing.com Nigeria

Jan 07, 2026

Dec 31, 2025

Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Allogene Therapeutics (ALLO) - The Globe and Mail

Dec 31, 2025

Dec 21, 2025

Is Allogene Therapeutics Inc. stock attractive for growth ETFsQuarterly Growth Report & Real-Time Volume Spike Alerts - Улправда

Dec 21, 2025

Dec 19, 2025

Why Allogene Therapeutics Inc. stock is seen as undervaluedMarket Activity Recap & Verified Stock Trade Ideas - Улправда

Dec 19, 2025

Dec 17, 2025

Allogene Therapeutics Earnings Notes - Trefis

Dec 17, 2025

Dec 16, 2025

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Benzinga

Dec 16, 2025

Dec 16, 2025

Allogene stock rises after favorable arbitration ruling reaffirms therapy rights By Investing.com - Investing.com South Africa

Dec 16, 2025

Dec 15, 2025

Allogene Therapeutics (ALLO) Solidifies Global Rights to Cema-ce - GuruFocus

Dec 15, 2025

Dec 15, 2025

Arbitration ruling reaffirms Allogene’s control of cancer therapy By Investing.com - Investing.com Canada

Dec 15, 2025

Dec 15, 2025

Arbitration ruling reaffirms Allogene’s control of cancer therapy - Investing.com India

Dec 15, 2025

Dec 15, 2025

Allogene Therapeutics Reaffirms Control of Cemacabtagene Ansegedleucel Following Arbitration Ruling - Quiver Quantitative

Dec 15, 2025

Dec 15, 2025

Allogene stock rises after favorable arbitration ruling reaffirms therapy rights - Investing.com

Dec 15, 2025

Dec 15, 2025

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - sahmcapital.com

Dec 15, 2025

Dec 15, 2025

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis - GlobeNewswire

Dec 15, 2025

Dec 15, 2025

Allogene (NASDAQ: ALLO) arbitration clears path to global cema-cel rights deal - Stock Titan

Dec 15, 2025

Dec 14, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Dec 14, 2025

Dec 12, 2025

December 2025 Penny Stocks Worth Watching - simplywall.st

Dec 12, 2025

Dec 09, 2025

Allogene Therapeutics advances ALPHA3 trial to battle relapse fears - Traders Union

Dec 09, 2025

Dec 04, 2025

Will Allogene Therapeutics Inc. stock benefit from green energy trendsForecast Cut & Stock Market Timing Techniques - Newser

Dec 04, 2025

Dec 04, 2025

Allogene Therapeutics showcases ALPHA3 study at ASH25 - Traders Union

Dec 04, 2025

Dec 01, 2025

Allogene Therapeutics CEO unveils pipeline at Piper Sandler - Traders Union

Dec 01, 2025

Nov 29, 2025

Allogene Therapeutics Up 19%, But Some Insiders Miss Out - 富途牛牛

Nov 29, 2025

Nov 29, 2025

Allogene Therapeutics (NASDAQ:ALLO) Upgraded at Wall Street Zen - MarketBeat

Nov 29, 2025

Nov 26, 2025

Could a New Alternative to a Bespoke Treatment Change the Future of Cancer Care? - Katie Couric Media

Nov 26, 2025

Nov 25, 2025

Allogene upgraded at Citizens after Q4 update - MSN

Nov 25, 2025

Nov 24, 2025

Allogene Therapeutics redefines CAR T-cell therapy with allogeneic products - Traders Union

Nov 24, 2025